KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:可得 入排置信度 0.98

BRUIN CLL-313: Randomized Phase III Trial of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

Wojciech Jurczak, Michal Kwiatek, Jaroslaw Czyz, Ederson Roberto de Mattos, Ki-Seong Eom, Alexander Egle, Anna Panovska, Zhanet Grudeva Popova, Hsuan-Jen Shih, Luis Felipe Casado Montero, Paolo Sportoletti, Vu Minh Hua, James T D'Olimpio, Shinsuke Iida, Rodrigo Ito, Katherine Bao, Anne Fink, Weiji Su, Amy S Ruppert, Alejandro Levy, Tomasz Wrobel

J Clin Oncol 44(6) 466-475

PMID41363773
PMCIDPMC12904224
DOI10.1200/JCO-25-02380
发表日期2025-12-09
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:历史记录已完成可用 Figure 视觉审查,未识别 KM 曲线。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 5 张 PMC Figure,均未识别为 KM 图:FIG 1.:CONSORT/入组流程图;FIG 2.:森林图/亚组分析图;FIG 3.:森林图/亚组分析图;FIG A1.:森林图/亚组分析图;FIG A2.:森林图/亚组分析图。
摘要

摘要

PURPOSE: BRUIN CLL-313 is a randomized, open-label, global phase III study comparing the efficacy and safety of pirtobrutinib, a highly selective, noncovalent Bruton tyrosine kinase inhibitor (BTKi), against bendamustine plus rituximab (BendaR), a common frontline chemoimmunotherapy, in treatment-naïve patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). METHODS: Patients with previously untreated CLL/SLL without del(17p) were randomly assigned 1:1 to continuous pirtobrutinib monotherapy or BendaR, stratified by immunoglobulin heavy chain gene mutation status and Rai stage. The primary end point was independent review committee (IRC)-assessed progression-free survival (PFS); secondary end points included overall survival (OS), investigator (INV)-assessed PFS, safety, and tolerability. RESULTS: Overall, 282 patients were randomly assigned to receive pirtobrutinib (n = 141) or BendaR (n = 141). IRC-assessed PFS was significantly improved with pirtobrutinib versus BendaR (hazard ratio [HR], 0.199 [95% CI, 0.107 to 0.367]; P < .0001), and the 24-month PFS rate was 93.4% (95% CI, 87.6 to 96.5) and 70.7% (95% CI, 61.5 to 78.1), respectively. INV-assessed PFS similarly favored pirtobrutinib (HR, 0.186 [95% CI, 0.093 to 0.371]). Interim analysis of OS favored pirtobrutinib (median follow-up 32 months; HR, 0.257 [95% CI, 0.070 to 0.934]) despite an effective crossover rate of 52.9%. In patients receiving pirtobrutinib versus BendaR: adverse event (AE)-related dose reductions occurred in 3.6% versus 31.1% of patients; grade ≥3 treatment-emergent AEs (TEAEs) occurred in 40.0% versus 67.4% of patients; and treatment discontinuations because of TEAEs occurred in 4.3% versus 15.2% of patients, respectively. CONCLUSION: Pirtobrutinib demonstrated superiority over BendaR in IRC-assessed PFS in treatment-naïve CLL/SLL. OS trends favored pirtobrutinib despite the study design allowing for crossover. Pirtobrutinib was well tolerated, consistent with its known safety profile, and more favorable than BendaR.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(5,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIG 1.Flow diagram. a Effective crossover rate uses the number of participants with INV-assessed progressive disease as the denominator. INV, investigator; ITT, intention-to-treat.
非 KM Figure
FIG 2.Kaplan-Meier curve of (A) IRC-assessed PFS and (B) IRC-assessed PFS by IGHV mutation status. BendaR, bendamustine plus rituximab; HR, hazard ratio; IGHV, immunoglobulin heavy chain gene; INV, Investigator; IRC, independent review committee; PFS, progression-free ssurvival.
非 KM Figure
FIG 3.Kaplan-Meier curve of OS. BendaR, bendamustine plus rituximab; HR, hazard ratio; OS, overall survival.
非 KM Figure
FIG A1.Kaplan-Meier curve of INV-assessed PFS. *Nominal P value. BendaR, bendamustine plus rituximab; HR, hazard ratio; INV, investigator; IRC, independent review committee; PFS, progression-free survival.
非 KM Figure
FIG A2.Forest plot of IRC-assessed PFS across patient subgroups. a HR and 95% CI based on the unstratified Cox regression model. b Rai stage is summarized for patients with CLL as reported in the EDC. c The <5 cm and <10 cm categories include patients with no measurable lymph node. d Complex karyotype was defined as ≥3 chromosomal abnormalities. BendaR, bendamustine plus rituximab; CLL, chronic lymphocytic leukemia; ECOG, Eastern Cooperative Oncology Group; EDC, electronic data capture; FISH fluorescence in situ hybridization; HR, hazard ratio; IGHV, immunoglobulin heavy chain gene; IRC, independent review committee; SLL, small lymphocytic lymphoma.
非 KM Figure